<?xml version="1.0" encoding="UTF-8"?>
<p id="p0090">Compound 
 <bold>4</bold> is another peptidomimetic M
 <sup>pro</sup> inhibitor co-crystallised in complex with SARS-CoV-2 M
 <sup>pro</sup> (
 <xref rid="f0030" ref-type="fig">Fig.Â 6</xref>b).
 <xref rid="b0395" ref-type="bibr">
  <sup>79</sup>
 </xref> It originated from previous campaigns targeting SARS-CoV M
 <sup>pro</sup>.
 <xref rid="b0460" ref-type="bibr">
  <sup>92</sup>
 </xref> Its Michael acceptor irreversibly modifies Cys145. Compound 
 <bold>4</bold> shows anti-SARS-CoV-2 activity in Vero cells.
</p>
